10.1016/s1470-2045(18)30354-1 - Once weekly versus twice weekly carfi...

This document has been corrected

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

10.1016/s1470-2045(18)30354-1

Published Online: 2018-07-?

Journal: The Lancet Oncology•Publisher: Elsevier BV

Authors: A Keith Stewart•Anita Zahlten-Kumeli•Antonio Lazzaro•James R Berenson•Katja Weisel•Kevin Song•Maria-Victoria Mateos•Mei Huang•Meletios A Dimopoulos•Philippe Moreau

This document has been corrected

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

10.1016/s1470-2045(18)30354-1

Published Online: 2018-07-?

Journal: The Lancet Oncology

Authors: A Keith Stewart•Anita Zahlten-Kumeli•Antonio Lazzaro•James R Berenson•Katja Weisel•Kevin Song•Maria-Victoria Mateos•Mei Huang•Meletios A Dimopoulos•Philippe Moreau

NOW

2018-08-01•Erratum

Correction to Lancet Oncol 2018; 19: 953–64

10.1016/s1470-2045(18)30492-3

* information provided by CrossRef

2018-08-01•Erratum

10.1016/s1470-2045(18)30492-3

* information provided by CrossRef

2018-07-?•Published

2018-08-01•Erratum

Correction to Lancet Oncol 2018; 19: 953–64

10.1016/s1470-2045(18)30492-3

* information provided by CrossRef

This document has been corrected

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

10.1016/s1470-2045(18)30354-1

Published Online: 2018-07-?

Journal: The Lancet Oncology•Publisher: Elsevier BV

Authors: A Keith Stewart•Anita Zahlten-Kumeli•Antonio Lazzaro•James R Berenson•Katja Weisel•Kevin Song•Maria-Victoria Mateos•Mei Huang•Meletios A Dimopoulos•Philippe Moreau